Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
Avutometinib
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT06072781IIIRecurrent low grade serous ovarian cancerA Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
NCT04625270IIRecurrent low grade serous ovarian cancerA Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)AZ, CA, CT, FL, IL, MD, MN, MO, NV, NM, NY, OH, OK, OR, TN, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.